Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
4
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
amgen
calcitonin gene-related peptide
cancer
drugs
eli lilly
eptinezumab
erenumab
fremanezumab
galcanezumab
migraine research foundation
novartis
What
fda
4
×
new
4
×
drug
approval
class
medicines
migraine
won
activity
amgen
approvals
approved
arguments
big
bio
biogen
cancer
candidates
clamped
commercialized
companies
competitors
covid
decades
deeper
delays
developed
developing
dna
drugs
economic
fast
fingerprint
genetic
gets
going
head
including
ipo
isn’t
Language
unset
Current search:
fda
×
new
×
" seattle blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
